Prothena Corp Public (PRTA) Total Non-Current Liabilities (2013 - 2026)
Prothena Corp Public's (PRTA) quarterly Total Non-Current Liabilities came in at $4.8 million in Q1 2026, down 48.23% year-on-year from $9.2 million in Q1 2025, and down 13.23% quarter-over-quarter from $5.5 million in Q4 2025.
Prothena Corp Public (PRTA) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Prothena Corp Public's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $4.8 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 48.23% year-over-year to $4.8 million in Q1 2026; TTM through Mar 2026 was $4.8 million, a 48.23% decrease from a year earlier, with the FY2025 full-year figure at $5.5 million, down 53.03% from the prior year.
- Total Non-Current Liabilities declined to $4.8 million in Q1 2026 per PRTA's latest filing, from $5.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $106.0 million in Q1 2022 and bottomed at $4.8 million in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $67.4 million (2023), against an average of $50.2 million.
- Across the five-year window, Total Non-Current Liabilities increased 7.25% in 2022 and plunged 88.14% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $85.8 million in 2022, then dropped by 8.99% to $78.1 million in 2023, then slumped by 85.05% to $11.7 million in 2024, then plunged by 53.03% to $5.5 million in 2025, then slipped by 13.23% to $4.8 million in 2026.
- Per Business Quant, the three latest PRTA Total Non-Current Liabilities figures stand at $4.8 million (Q1 2026), $5.5 million (Q4 2025), and $6.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - | 4.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.76 Mn |
| Dec 31, 2025 | 5.49 Mn |
| Sep 30, 2025 | 6.20 Mn |
| Jun 30, 2025 | 6.93 Mn |
| Mar 31, 2025 | 9.20 Mn |
| Dec 31, 2024 | 11.68 Mn |
| Sep 30, 2024 | 14.47 Mn |
| Jun 30, 2024 | 16.90 Mn |
| Mar 31, 2024 | 77.53 Mn |
| Dec 31, 2023 | 78.13 Mn |
| Sep 30, 2023 | 76.32 Mn |
| Jun 30, 2023 | 67.41 Mn |
| Mar 31, 2023 | 85.29 Mn |
| Dec 31, 2022 | 85.85 Mn |
| Sep 30, 2022 | 99.19 Mn |
| Jun 30, 2022 | 102.18 Mn |
| Mar 31, 2022 | 106.03 Mn |
| Dec 31, 2021 | 109.87 Mn |
| Sep 30, 2021 | 113.03 Mn |
| Jun 30, 2021 | 95.27 Mn |